ArticleBioengineering (Basel, Switzerland)2026
Predicting Recurrence Risk of Glioblastoma Based on Preoperative-Postoperative Longitudinal MRI: A Multicenter Study.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Glioblastoma has a high recurrence rate, yet conventional single-time-point imaging fails to capture the dynamic tumor evolution before and after surgery. This study aims to develop a deep learning model based on preoperative and postoperative longitudinal MRI to predict postoperative recurrence risk by capturing imaging dynamics. We propose MambaDiff-Net, which employs a dual-stream encoder to extract multi-scale features from preoperative and postoperative T2WI. It also includes a feature discrepancy computation module to model longitudinal imaging changes, outputting individualized recurrence risk probabilities. We included 139 patients with glioblastoma (59 training, 40 internal validation, 40 external test), with recurrence within 6 months post-surgery as the prediction target. Performance was evaluated using AUC, accuracy, and F1. MambaDiff-Net achieved AUCs of 0.887 and 0.762 in internal and external validation, respectively, significantly outperforming single-time-point models. Kaplan-Meier analysis demonstrated effective risk stratification, and decision curve analysis confirmed superior clinical net benefit. Grad-CAM visualization showed the model's focus shifting from preoperative tumor parenchyma to postoperative resection cavity margins, consistent with clinical knowledge. A deep learning model based on preoperative-postoperative longitudinal MRI can accurately predict postoperative recurrence risk in glioblastoma. By modeling dynamic imaging changes before and after surgery, it supports individualized treatment decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.